Efficacy and safety of recombinant human interleukin -2 in the adjuvant treatment of relapsing infiltrative pulmonary tuberculosis

Abstract

Objective: To study the efficacy and safety of recombinant human interleukin-2 in the adjuvant treatment of relapsing infiltrative pulmonary tuberculosis. Methods: 198patients with reactivation tuberculosis were randomly divided into the test group and the control group. The dosing regimen was anti-tubercular agents and recombinant human interleukin-2 in the test group, and only the anti-tubercular agents in the control group. Conventional dose of anti-tubercular agents according to the clinical application of recombinant human interleukin-2 is 200 000 units. Results: The rate of sputum negative conversion and rate of focus absorption in the test group was higher than that in the control group (P<0.05). Although the rate of cavity closure in the test group is higher than the control group. Compared with the two groups the differences were not statistically significant (P>0.05). The ratio of CD4 and CD4/CD8 in the test group increased significantly at the third, and eighth months after the treatment, and it had the statistical significance compared with the control group (P<0.05).The level of soluble interleukin-2 receptors in the test group decreased significantly, and it had significantly differences compared with the control group (P<0.05).No serious adverse events were reported in the two groups. Conclusions: Recombinant human interleukin-2 is safe and effective as adjuvant treatment of relapsing infiltrative pulmonary tuberculosis. [Cui Deguang, Zhu Wenjuan. Efficacy and safety of recombinant human interleukin -2 in the adjuvant treatment of relapsing infiltrative pulmonary tuberculosis. Life Sci J 2014; 11(7):543-547] (ISSN: 1097-8135). http://www.lifesciencesite.com. 73

4 Figures and Tables

Cite this paper

@inproceedings{Deguang2014EfficacyAS, title={Efficacy and safety of recombinant human interleukin -2 in the adjuvant treatment of relapsing infiltrative pulmonary tuberculosis}, author={Cui Deguang and Zhu Wenjuan}, year={2014} }